Supernus Pharmaceuticals(SUPN) - 2025 Q3 - Quarterly Results

Form 8-K Filing Details This section provides the foundational details of the Form 8-K filing, including registrant identification and filing specifics Registrant Information This section provides the core identification details for Supernus Pharmaceuticals, Inc. as the registrant, including its incorporation state, commission file number, principal executive offices, and securities registered on Nasdaq - Registrant: Supernus Pharmaceuticals, Inc.[2] Registrant Details | Detail | Value | | :--- | :--- | | State of Incorporation | Delaware | | Commission File Number | 001-35518 | | I.R.S. Employer Identification No. | 20-2590184 | | Principal Executive Offices | 9715 Key West Ave, Rockville MD 20850 | | Registrant's Telephone Number | (301) 838-2500 | Registered Securities | Title of Class | Trading Symbol | Exchange | | :--- | :--- | :--- | | Common Stock, $0.001 par value per share | SUPN | The Nasdaq Stock Market LLC | Filing Specifics The report confirms the filing date and indicates that Supernus Pharmaceuticals, Inc. is not an emerging growth company - Date of Report (Date of earliest event reported): October 21, 2025[2] - The registrant is not an emerging growth company[3] Current Report Items This section details the specific events reported in the Form 8-K, covering financial results and required exhibits Item 2.02 Results of Operations and Financial Condition Supernus Pharmaceuticals, Inc. announced its plan to release third-quarter 2025 business results and host a conference call and webcast on November 4, 2025, to discuss these financial and business outcomes - Supernus Pharmaceuticals, Inc. expects to report its Q3 2025 business results after market close on Tuesday, November 4, 2025[4] - A conference call and webcast will be held on Tuesday, November 4, 2025, at 4:30 p.m. E.T. to discuss the results[4] - A press release dated October 21, 2025, is furnished as Exhibit 99.1[4] Item 9.01 Financial Statements and Exhibits This section lists the exhibits filed with the Form 8-K, including the press release regarding Q3 2025 results and the Inline XBRL formatted cover page Exhibits Filed | Exhibit Number | Description | | :--- | :--- | | 99.1 | Press Release dated October 21, 2025 filed as an Exhibit pursuant to Item 2.02 hereof | | 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | Signatures This section confirms the official authorization and signatory details for the Form 8-K filing Authorization and Signatory The report was duly signed on behalf of Supernus Pharmaceuticals, Inc. by Timothy C. Dec, Senior Vice President and Chief Financial Officer, on October 21, 2025 - Report signed on behalf of Supernus Pharmaceuticals, Inc.[9] - Signatory: Timothy C. Dec, Senior Vice President and Chief Financial Officer[10] - Date of Signature: October 21, 2025[10]